Showing 2644 results
- Media Release /Der Nettoumsatz (0% kWk[2]) bleibt im Gesamtjahr dank starker Performance der Wachstumsprodukte auf Vorjahresniveau Cosentyx (USD 1,1 Milliarden) erreicht Blockbuster-Status Entresto (USD 170…
- Media Release /Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with…
- Media Release /Cosentyx® delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years[1] New data show…
- Media Release /ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo…
- Media Release /Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need Sandoz "HACk" - Healthcare Access Challenge - is…
- Media Release /Ilaris® (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease These three simultaneous approvals conducted under FDA…
- Media Release /In a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global…
- Media Release /Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites…
- Media Release /New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
- Media Release /EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary…
Pagination
- ‹ Previous page
- 1
- …
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- …
- 265
- › Next page